Skip to content

Effect of dexamethasone and dexmedetomidine as local anesthetic adjuvants for erector spinae plane block and serratus anterior plane block on analgesic after thoracoscopic surgery:a prospective, randomized controlled trial

Effect of dexamethasone and dexmedetomidine as local anesthetic adjuvants for erector spinae plane block and serratus anterior plane block on analgesic after thoracoscopic surgery: a prospective, randomized controlled trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400087957
Enrollment
Unknown
Registered
2024-08-07
Start date
2024-08-09
Completion date
Unknown
Last updated
2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative pain

Interventions

Ropivacaine group (group R):Local anesthetic liquid configuration: 40ml solution (containing 0.375% ropivacaine)
Dexamethasone as a ropivacaine adjuvant group ((group RS):Local anesthetic liquid configuration: 40ml solution (containing 0.375% ropivacaine + 10mg dexamethasone)
Dexmedetomidine as a ropivacaine adjuvant group ((group RM):Local anesthetic liquid configuration: 40ml solution (containing 0.375% ropivacaine + 1 µg/kg dexmedetomidine)
Mixture of dexamethasone and dexmedetomidine as a ropivacaine adjuvant group (group RSM):Local anesthetic liquid configuration: 40ml solution (containing 0.375% ropivacaine + 10mg dexamethasone + 1µg/

Sponsors

The Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Age 18-65 years old; (2) ASAI.-III. (3) elective unilateral VATS;

Exclusion criteria

Exclusion criteria: (1) Contraindications to regional nerve blocks, including skin infections or bleeding disorders at the site of the block; (2) Those who are allergic to any of the drugs used in this test and have contraindications; (3) Patients with severe cardiovascular and cerebrovascular diseases, respiratory diseases, diabetes mellitus and abnormal liver and kidney function before surgery; (4) History of chronic pain, long-term use of opioids, hormones or non-steroidal drugs; (5) Those who are unable to communicate normally: hearing impairment, language comprehension impairment, mental illness, etc.; (6) Bradycardia (< 50 beats/min); (7) BMI=30 kg/m^2; (8) Those who have participated in other investigators;

Design outcomes

Primary

MeasureTime frame
Effective analgesic duration;

Secondary

MeasureTime frame
NRS score;PCIA;Total opioid consumption of PCIA after surgery;Remedial analgesia;Postoperative recovery index;Ramsay rating;QoR-15 rating;Patient satisfaction;Intraoperative opioid dosage;Blood pressure, heart rate, SpO2 at different time points;The occurrence of intraoperative adverse reactions;Postoperative complications;

Countries

China

Contacts

Public ContactLinlin Zhao

The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu Province

lin1675@163.com+86 181 6877 7313

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026